sur Emerald Clinical Trials
Emerald Clinical Trials Welcomes Michael Stibilj as New CEO
Emerald Clinical Trials, a prominent clinical research organization based in Asia-Pacific, announces Michael Stibilj's appointment as Chief Executive Officer on October 1, 2026. Stibilj, with over 30 years in the global CRO industry, will lead the company into its next growth phase.
Stibilj brings a wealth of experience, having previously served as COO at Novotech and CEO at PPC Group. His expertise spans transformational leadership and significant revenue growth, especially within the Asia-Pacific region.
This leadership change comes after Emerald Clinical's acquisition of Hongyi Clinical Development Services, expanding its capabilities to over 1,000 professionals globally. The company is positioned as a leading platform in clinical development, spanning 40+ countries.
The board expresses confidence in Stibilj's ability to guide Emerald Clinical's future, leveraging his global insight and Asia-Pacific depth to enhance the company's market position.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Emerald Clinical Trials